As the first PI3K inhibitors were emerging in the clinic, we and others studied their effects on ER signaling with the goal of identifying the most effective combinatorial therapy for ER+/PIK3CA mutant breast cancer. The gene discussed is PIK3CA; the disease is breast cancer.